Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog.
1. Single oral doses of 14C-5-methoxypsoralen (5-MOP) to human subjects (50 mg), rats (1 mg/kg) and dogs (1 mg/kg) were fairly well absorbed but subjected to extensive first-pass metabolism, at least in rat and human. Means of 62, 51 and 40% dose in urine and 31, 38 and 48% dose in faeces, were excreted by humans (during 5 days), rats (3 days) and dogs (1 day), respectively. In dogs, faecal 14C was probably derived, in part, from biliary excreted material. 2. Total 14C in human plasma reached peak concentrations after 2 h (mean 235 ng 5-MOP equivalent/ml) and declined relatively slowly, to about 60% of this value within 24 h. Unchanged 5-MOP was not detected in plasma using h.p.l.c. (< 5 ng/ml). 3. Tissue concentrations of 14C were generally greater in dogs than rats and reached peak levels at 1 h in dogs but at 24 h in rats. Apart from liver and bile, dog tissue 14C concentrations were lower than those in the corresponding plasma, whereas in rat they were lower only until the time of peak concentrations, after which they were generally greater. 4. 5-MOP was extensively metabolized in all three species. The major 14C-components in human and dog urine were glucuronic acid conjugates, mainly of an arylacetic acid and arylalcohols, resulting from initial oxidative metabolism of the furan ring of 5-MOP. In rat, these metabolites were excreted mainly unconjugated. An unusual metabolite was formed by reduction of the lactone moiety of 5-MOP, probably by the gut flora, giving rise to an arylpropionic acid, excreted as a glucuronic acid conjugate in the urine of all three species. 5. Unchanged drug was a very minor component of human and rat plasma, but a major component of dog plasma. In all three species, circulating 14C-metabolites were similar to those in the urine but were present mainly unconjugated. On the basis of these data, the metabolic fate of 5-MOP in humans was more similar to that in dog than to that in rat, although humans appeared to metabolize 5-MOP more rapidly than did dog.
John
B A
BA
Department of Metabolism and Pharmacokinetics, Huntingdon Research Centre Ltd, Cambridgeshire, UK.
Chasseaud
L F
LF
Wood
S G
SG
Forlot
P
P
D000078223:5-Methoxypsoralen; D000328:Adult; D000818:Animals; D001646:Bile / Q000378:metabolism; D002432:Cecum / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D005243:Feces; D005966:Glucuronidase / Q000378:metabolism; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008730:Methoxsalen / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D051381:Rats; D013045:Species Specificity; D014018:Tissue Distribution
D000078223:5-Methoxypsoralen; D005966:Glucuronidase; D008730:Methoxsalen